XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.33

-8.6%

Jan 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert S. who wrote (9315)	3/21/1999 11:18:00 PM
From: Cacaito	Read Replies (3) of 17367

Robert S, show me the completed phase III on all the drugs you and StockDoc mentioned and I will buy the correspondent stock ipso facto. Even if any of then are proven effective (long way) they will be 2ry adjuvants (if at all) to Bpi. Bpi has practically no side effect. Antithrombin III will lead to massive bleeding the toxic dose is to near the effective dose. Protein C, and activated protein C could lead to massive hypercoagulation (the opposite of AIII) same problem of effective dose to near the toxic dose. Bpi is a clean molecule (not a scientific term but it does sound neat). Tpa has probably a better chance (GNE).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next